These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3930072)

  • 21. In vitro migration of tumor cells from human neoplasms: inhibition by lymphokines.
    Cohen MC; Forouhar F; Donskoy M; Cohen S
    Clin Immunol Immunopathol; 1985 Jan; 34(1):94-9. PubMed ID: 3965225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of plasminogen-activator in mastocytoma cells by lymphokines.
    Kramer M; Woodbury RG; Schirrmacher V; Robinson P
    Immunobiology; 1983 Jul; 165(1):107-12. PubMed ID: 6411606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of lymphokines affecting tumor cells by T-T hybridomas.
    Cohen MC; Lazarus M
    Cell Immunol; 1985 Jul; 93(2):541-8. PubMed ID: 4005960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific reversal of cytolytic T cell-target cell functional binding is induced by free target cells.
    Balk SP; Mescher MF
    J Immunol; 1981 Jul; 127(1):51-7. PubMed ID: 6787131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigenic changes of DBA/2J mastocytoma cells when grown in the BALB/c mouse.
    Wolf JE; Faanes RB; Choi YS
    J Natl Cancer Inst; 1977 May; 58(5):1407-12. PubMed ID: 67213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Humoral mechanisms of in vitro inhibition of mouse lymphocyte immunoreactivity by mastocytoma P815 cells].
    Medvedev AE
    Biull Eksp Biol Med; 1988 Jun; 105(6):701-3. PubMed ID: 2968820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Production of a factor inhibiting tumor cell migration by spleen cells from tumor-bearing mice.
    Raichev I; Dotchevska R
    Jpn J Med Sci Biol; 1988 Apr; 41(2):49-56. PubMed ID: 3241459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Further characterization of macrophage adsorption of suppressor cell activity from tumor-allosensitized spleen.
    Zografos-Miller LE; Argyris BF
    Transplantation; 1983 Jun; 35(6):593-600. PubMed ID: 6223418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrophage activation: synergism between hybridoma MAF and poly(I). Poly(C) delivered by liposomes.
    Pidgeon C; Schreiber RD; Schultz RM
    J Immunol; 1983 Jul; 131(1):311-4. PubMed ID: 6408176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-dependent cell-mediated damage of target cells.
    Scornik JC; Klein PA
    Transplantation; 1978 Nov; 26(5):356-7. PubMed ID: 100916
    [No Abstract]   [Full Text] [Related]  

  • 31. [Macrophage depletion test in guinea pigs].
    Zschiesche W
    Allerg Immunol (Leipz); 1976; 22(1):105-8. PubMed ID: 135493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High strength binding of P815 mastocytoma cells is not necessary for their lysis by macrophages which have been primed and triggered in vitro.
    Lu CY; Lombardi MJ; Shea CM; Dustin LB
    J Immunol; 1988 Aug; 141(4):1083-90. PubMed ID: 3135320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of T cells in tumor-bearing mice.
    Behforouz NC; Cerny J; Eardley DD
    Cell Immunol; 1983 Jul; 79(1):93-109. PubMed ID: 6407765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
    Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
    J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of concanavalin A treatment on the allogeneic response of mice to challenge with P 815 mastocytoma: interleukin 2 treatment reverses concanavalin A suppression in vivo.
    Ekstedt RD; Merdian DJ
    Cell Immunol; 1984 May; 85(2):447-58. PubMed ID: 6424952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences.
    Kamate C; Baloul S; Grootenboer S; Pessis E; Chevrot A; Tulliez M; Marchiol C; Viguier M; Fradelizi D
    Int J Cancer; 2002 Aug; 100(5):571-9. PubMed ID: 12124807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of suppressor cells in mice bearing syngeneic mastocytoma.
    Takei F; Levy JG; Kilburn DG
    J Immunol; 1977 Feb; 118(2):412-7. PubMed ID: 65423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
    Wenkel H; Chen PW; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of humoral factors of the mastocytoma P815 cells on the formation of allospecific killers in mixed culture of lymphocytes and their cytotoxic activity].
    Medvedev AE; Dostman U; Flegel' A
    Biull Eksp Biol Med; 1989 Aug; 108(8):224-6. PubMed ID: 2529921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppressor factor from tumor-allosensitized spleen cells--its effect on in vitro proliferation of tumor cells and in vivo skin allograft survival.
    Argyris BF
    Cell Immunol; 1981 Jan; 57(1):62-72. PubMed ID: 6452215
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.